Corbus Pharmaceuticals (NASDAQ:CRBP)‘s stock had its “buy” rating reiterated by research analysts at Noble Financial in a research note issued on Friday, December 29th.
Other analysts also recently issued research reports about the stock. Cantor Fitzgerald reissued a “buy” rating and issued a $24.00 price objective on shares of Corbus Pharmaceuticals in a report on Wednesday, September 20th. BidaskClub raised shares of Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, December 29th. Finally, ValuEngine downgraded shares of Corbus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, September 13th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $25.00.
Corbus Pharmaceuticals (NASDAQ CRBP) opened at $8.20 on Friday. Corbus Pharmaceuticals has a 52 week low of $5.30 and a 52 week high of $10.50. The company has a market cap of $449.96, a PE ratio of -13.23 and a beta of 174.68.
Corbus Pharmaceuticals (NASDAQ:CRBP) last announced its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.16) by $0.02. The business had revenue of $0.80 million for the quarter. Corbus Pharmaceuticals had a negative net margin of 1,040.41% and a negative return on equity of 96.02%. equities research analysts expect that Corbus Pharmaceuticals will post -0.6 earnings per share for the current year.
In other Corbus Pharmaceuticals news, Director David P. Hochman purchased 10,000 shares of the firm’s stock in a transaction on Friday, November 10th. The stock was purchased at an average cost of $7.08 per share, for a total transaction of $70,800.00. Following the transaction, the director now owns 459,500 shares in the company, valued at approximately $3,253,260. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director David P. Hochman purchased 5,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was acquired at an average price of $6.90 per share, with a total value of $34,500.00. The disclosure for this purchase can be found here. In the last ninety days, insiders have bought 25,336 shares of company stock valued at $175,632. 11.90% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. State Board of Administration of Florida Retirement System acquired a new stake in shares of Corbus Pharmaceuticals during the third quarter worth $108,000. Yellowstone Partners LLC acquired a new stake in shares of Corbus Pharmaceuticals during the third quarter worth $110,000. Credit Suisse AG acquired a new stake in shares of Corbus Pharmaceuticals during the first quarter worth $157,000. Voya Investment Management LLC acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter worth $125,000. Finally, Capital Fund Management S.A. acquired a new stake in shares of Corbus Pharmaceuticals during the second quarter worth $130,000. Hedge funds and other institutional investors own 27.84% of the company’s stock.
Corbus Pharmaceuticals Company Profile
Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.
Receive News & Ratings for Corbus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.